Can Pan-TB shorter regimens be a promising hope for ending TB in India by 2025 in ongoing COVID-19 era?

Prasad, Rajendra; Singh, Abhijeet; Gupta, Nikhil

Prasad, Rajendra; Singh, Abhijeet; Gupta, Nikhil.

Prasad R; Department of Pulmonary Medicine, Era Medical College, Lucknow, Uttar Pradesh, India. Electronic address: rprasadkgmc@gmail.com.
Singh A; Department of Pulmonary & Critical Care Medicine, Fortis Hospital, Vasant Kunj, New Delhi, India.
Gupta N; Department of Internal Medicine, Dr Ram Manohar Lohia Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.

Indian J Tuberc ; 69(4): 377-382, 2022 Oct.

Article in English | MEDLINE | ID: covidwho-1907205

Subject(s)

COVID-19; Humans; COVID-19/prevention & control; Longitudinal Studies; India/epidemiology

Keywords

Drug resistant; Drug sensitive; Shorter; Tuberculosis; Universal regimen

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Observational study / Prognostic study Limits: Humans Country/Region as subject: Asia Language: English Journal: Indian J Tuberc Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google